Hypoxia Imaging With FAZA-PET and Theoretical Considerations With Regard to Dose Painting for Individualization of Radiotherapy in Patients With Head and Neck Cancer

Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers

“…Others have previously shown that dose escalation of the PET abnormality is feasible in select patients [24,30,31]. Such areas could be part of a simultaneous integrated boost [32,33]. It is unclear whether these targets for dose escalation should be defined by, visual interpretation [11], a threshold intensity plateau [28], or if the boost dose intensity should be specifically tailored to each imaging voxel intensity (i.e.…”

“…In addition, other areas that warrant attention include the assessment of the FDG signal during treatment to see if they correlate with treatment outcomes [39]. Finally, different forms of biological imaging agents or protocols that examine perfusion and hypoxia [33,40], may also warrant further study.…”

Development of 68Ga-labeled multivalent nitroimidazole derivatives for hypoxia imaging

“…The radical anion appears to undergo additional reduction and binds to macromolecules, and thus the associated radiolabel is selectively retained in hypoxic cells. This under Figure 3) [7][8][9], [ [10][11][12][13] [15], which is a more hydrophilic nitroimidazole compound and shows rapid elimination of non-target tissues via excretion through the urinary pathway. [ (2,2,3,3,3-pentafluoropropyl) [14] are other known hypoxia imaging agents ( Figure 3) developed to improve the imaging performance by improving target to non-target ratio by increasing excretion rates.…”

Current Molecular Imaging Positron Emitting Radiotracers in Oncology

“…18 F-Fluoroazomycin arabinoside ( 18 F-FAZA), another 18 F-labeled 2-nitroimidazole derivative, has better pharmacokinetics than 18 F-FMISO with higher tumor-to-background, tumor-to-muscle and tumor-toblood ratios due to its more rapid clearance from blood and non-target tissues [94,95]. 18 F-FAZA imaging provides similar hypoxia information to 18 F-FMISO, which may be helpful for therapy planning [96]. In addition, Lehtiö et al [97] [103,104].…”